Although research into urine- and image-based alternatives continues, there is no established replacement for cystoscopy.
Urothelial Carcinoma Diagnostics
Advertisement
Researchers find promise for ctDNA-guided immunotherapy for patients with MIBC who underwent radical cystectomy.
John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field.
Dr. Koshkin highlights emerging data on Nectin-4–targeted imaging and radiopharmaceuticals in urothelial cancer.
Dr. Koshkin shares an overview of FAP-targeted theranostics, including UCSF-led studies showing FAP PET imaging’s ability.
Previous research has shown that BLC can provide improved detection rates, mainly for high-risk disease and invasive tumors.
This newly developed assay can assess the genomic profile of ctDNA in patients with advanced UC.
Dr. Lotan discusses risk stratification and outlines the next steps for integrating Cxbladder Triage into clinical practice.
Dr. Lotan describes the design and key findings of the STRATA trial using Cxbladder Triage for patients with microhematuria.
Dr. Jensen highlights the single-arm trial design and TOMBOLA's use of ctDNA.
ctDNA testing may help identify patients with bladder cancer who would benefit from early post-cystectomy immunotherapy.
Video Insights
Conference Coverage
Researchers investigated the efficacy of platinum plus 5-FU in the treatment of patients with high-risk penile cancer.
Dr. Attard explores how the study's results compare with prior data in the metastatic castration-resistant setting.
Avelumab plus sacituzumab govitecan may improve PFS in patients with advanced bladder cancer.
At 12 months, the OS rate for patients who received treatment with ipilimumab plus nivolumab was superior to SOC.
The Two Onc Docs review QOL related to doublet ADT with darolutamide, niraparib with abiraterone for mCSPC, and more.
The Two Onc Docs review the 5-year follow-up data on adjuvant pembro and a final analysis on ipi/nivo for metastatic disease.
Advertisement
Advertisement
Trending
These findings highlight the need for continued development and refinement of standardized HER2 testing methods.
Avelumab plus sacituzumab govitecan may improve PFS in patients with advanced bladder cancer.
The study’s major efficacy outcomes included a complete response in 78% of patients.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.